Table 2. Results of PML–RARA detection by PCR and the immunobead assay performed in 163 patient samples.
| Newly diagnosed patients | No. of patients | PML–RARA mRNA positive |
PML–RARA immunobead assay |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Positive |
MFI positive |
MFI negative |
Mean | 3-s.d. | |||||
| Median | Range | Median | Range | ||||||
| APL (AML-M3) | 46 | 46 | 46 | 1514 | 192–32.160 | NA | NA | NA | NA |
| AML, non-APL | 66 | 0 | 0 | NA | NA | 114 | 100–173 | 121 | 55 |
| CML accelerated phase | 1 | 0 | 0 | NA | NA | 131 | NA | NA | NA |
| BCP-ALL | 34 | 0 | 0 | NA | NA | 115 | 106–151 | 118 | 31 |
| T-ALL | 16 | 0 | 0 | NA | NA | 113 | 113–130 | 113 | 26 |
| Total | 163 | 46 | 46 | 1514 | 192–32.160 | 114 | 100–173 | 119 | 46 |
Abbreviations: AML-M3, acute myeloid leukemia type M3; APL, acute promyelocytic leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; CML, chronic myeloid leukemia; NA, not applicable.